Clinical Trials Browser

Interventional × Mast Cell Activation Disorders × Myeloid × Clear all

NCT02571036 2023-12-13

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Phase 1 Completed

CNSDermatologicGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmSarcomaThoracic

Mast Cell Activation Disorders, Carcinoma, Non-Small-Cell Lung, Glioma, Leukemia, Mast-Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Penile Neoplasms, Sarcoma, Mastocytosis, Systemic, Gastrointestinal Stromal Tumors, Renal Insufficiency

NCT01297777 2016-08-29

Imatinib in KIT-negative Systemic Mastocytosis

Phase 4 Completed

Mast Cell Activation Disorders, Mastocytosis, Mastocytosis, Systemic

NCT01602939 2016-08-29

Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis

Phase 2/3 Unknown

Mast Cell Activation Disorders, Mastocytosis, Mastocytosis, Systemic